Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Other Non-current Liabilities
Long-term obligations not reported separately, such as lease or pension liabilities.
Apogee Therapeutics, Inc.NASDAQ: APGE
Other Non-current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Other non-current liabilities remains negative
Q2 FY2026 other non-current liabilities was $99.23M, compared with $0 a year earlier.
Context
- Other non-current liabilities amounted to 7.4% of total assets at the end of Q2 FY2026, up 7.4 pp from a year earlier.
- Other non-current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Other Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Other Non-current Liabilities vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Other non-current liabilities amounts to 7.4% of total assets for APGE, versus a peer median of 0.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $110.47M USD | +380827.6% | — | 17.2% | |
| Jun 2026 | $99.23M USD | — | — | 7.4% | |
| Mar 2026 | $42M USD | -94.8% | — | 3.2% | |
AAPGAscentage Pharma Group International | Dec 2025 | CN¥12.04M CNY | +91.9% | -30.2% | 0.3% |
| Sep 2026 | $7.6M USD | -6.5% | +225.0% | 0.5% | |
| Sep 2026 | $3.33M USD | +5.4% | — | 0.3% | |
| Sep 2026 | $855K USD | -77.5% | +70.4% | 0.1% | |
| Jun 2026 | $225K USD | -30.8% | — | 0.0% | |
| Jun 2026 | $0 USD | — | — | 0.0% | |
IRONDisc Medicine, Inc. | Sep 2026 | $0 USD | -100.0% | — | 0.0% |
| Peer median (excluding APGE) | — | -18.6% | +70.4% | 0.3% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.